Resource Hub
A consolidated directory of advocacy organizations, pharmaceutical companies, epinephrine access programs, emergency guidance, and educational tools for the allergy and asthma community.
Pharmaceutical Companies & What They Do
The companies developing and manufacturing epinephrine devices, asthma biologics, food allergy immunotherapies, and treatments for allergic and eosinophilic diseases — with their key products and focus areas.
Epinephrine auto-injectors
Global healthcare company formed from the merger of Mylan and Upjohn. Manufacturer of the EpiPen, the most widely recognized epinephrine auto-injector.
Company websiteEpinephrine distribution & biologics
Distributes EpiPen in the U.S. Also develops JAK inhibitors for atopic dermatitis and other allergic/inflammatory conditions.
Company websiteEpinephrine auto-injectors
Specialty pharma focused on auto-injector innovation. Auvi-Q is the only epinephrine device with built-in voice instructions and auto-retracting needle.
Company websiteEpinephrine & asthma rescue
Specialty pharma developing inhalation and injection products. Manufactures Symjepi epinephrine syringe and the OTC Primatene Mist asthma inhaler.
Company websiteNasal epinephrine
Pioneered the first FDA-approved needle-free epinephrine nasal spray (neffy, approved 2024). Focuses on making emergency treatment more accessible.
Company websiteBiologics for allergic disease
Co-developed Dupixent with Sanofi — a blockbuster biologic approved for atopic dermatitis, asthma, EoE, COPD, and chronic rhinosinusitis with nasal polyps.
Company websiteBiologics & immunology
Global pharma leader in immunology and rare disease. Co-developer of Dupixent, the first biologic approved for eosinophilic esophagitis.
Company websiteBiologics for asthma & CSU
Xolair is approved for moderate-to-severe asthma, chronic spontaneous urticaria, and nasal polyps. In 2024, became the first medicine FDA-approved to reduce allergic reactions to multiple foods.
Company websiteAsthma biologics & respiratory
Leader in respiratory medicine. Fasenra targets eosinophilic asthma; Tezspire blocks TSLP for severe asthma. Broad portfolio of inhaled therapies.
Company websiteEosinophilic asthma & respiratory
Nucala was the first anti-IL-5 biologic approved for severe eosinophilic asthma, also approved for EGPA, HES, and chronic rhinosinusitis with nasal polyps.
Company websiteGeneric epinephrine & rescue inhalers
Produced the first FDA-approved generic EpiPen. Also manufactures rescue inhalers (ProAir HFA) and combination inhalers for asthma.
Company websiteEpicutaneous immunotherapy (EPIT)
Biotech developing Viaskin — a skin patch delivering peanut protein for desensitization. Focused on needle-free, non-oral immunotherapy for food allergies.
Company websiteAllergen immunotherapy
Global leader in allergy immunotherapy, offering both subcutaneous (SCIT) and sublingual (SLIT) allergy drops/tablets for environmental allergies.
Company websiteEosinophilic & mast cell disease
Clinical-stage biotech developing therapeutics for eosinophilic and mast cell mediated diseases including EoE, EGID, and chronic urticaria.
Company websiteAllergy immunotherapy
European biopharma specializing in allergy immunotherapy for respiratory and venom allergies. Developing modified allergens for safer desensitization.
Company websiteFood allergy immunotherapy
Developed Palforzia — the first FDA-approved treatment for peanut allergy (2020). Nestlé discontinued Palforzia in 2024, but research in oral immunotherapy continues.
Company websiteSublingual film drug delivery
Specialty pharma leveraging its PharmFilm® technology to develop Anaphylm™ (dibutepinephrine) — the first orally delivered sublingual film formulation of epinephrine, in clinical development for the emergency treatment of anaphylaxis. FDA accepted the New Drug Application in 2025.
Company websiteWhile we strive for accuracy, information may change over time. Always double-check and verify against official sources before relying on it.